The hiring of a Clinical Research Associate by Microbot Medical is a direct response to the positive results from its pre-clinical study and is a critical step towards the commencement of human clinical trials. This development is likely to be viewed positively by investors as it demonstrates the company's progress in its product pipeline and regulatory pathway. The anticipation of an IDE submission can often lead to increased investor interest and potentially a rise in stock price in the short term.